Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration

The pharmacokinetics of oxytetracycline (OTC) in three weaned piglets was studied following three routes of administration: intravenously, orally as drench, both at a dose of 20 mg/kg, and orally as medicated (400 ppm OTC) pelleted feed administered during 3 consecutive days. Analysis of the intravenous data according to the three compartment pharmacokinetic model revealed that OTC was well distributed in the body (Vf: 1.62 l/kg), had an overall body clearance of 0.25 litre/kg/h, and the elimination half-lives were in the range between 11.6 and 17.2 hrs. The mean OTC binding to plasma proteins was 75.5 +/- 4%. Following the drench route of administration the maximum plasma OTC concentration was achieved between 1 and 5 h post application and ranged between 1.18 and 1.41 micrograms/ml. The mean maximum plasma OTC concentration during medicated feed administration was 0.20 +/- 0.06 microgram/ml, which was achieved approximately 30 hours after the onset of the administration. A steady state OTC plasma level (approximately 0.2 microgram/ml) was maintained till the end of the trial. Within 48 hours after cessation of medicated feed administration the plasma OTC levels were beneath 0.06 microgram/ml. The mean OTC bioavailabilities of the oral routes were low: after the drench route of administration 9.0 +/- 0.67%, and after medicated pelleted feed administration 3.69 +/- 0.8%. The mean OTC renal clearances of each piglet ranged between 10.1 and 13.9 ml/min/kg (based on free OTC plasma fractions). The renal OTC clearance values were urine flow dependent in all piglets and significantly correlated with the renal creatinine clearance (P less than 0.005), being 3-5 times higher than the latter. It is concluded that in piglets OTC is excreted mainly by glomerular filtration and partly by tubular secretion. The potential clinical efficacy of 400 ppm OTC as medicated feed with respect to treatment, e.g. atrophic rhinitis, is discussed.     

Pharmacokinetics and renal clearance of oxytetracycline in piglets following intravenous and oral administration

Summary

The pharmacokinetics of oxytetracycline (OTC) in three weaned piglets was studied following three routes of administration: intravenously, orally as drench, both at a dose of 20 mg/kg, and orally as medicated (400 ppm OTC) pelleted feed administered during 3 consecutive days. Analysis of the intravenous data according to the three compartment pharmacokinetic model revealed that OTC was well distributed in the body (Vie 1.621/kg), had an overall body clearance of 0.25 litre/kg/h, and the elimination half‐lives were in the range between 11.6 and 17.2 hrs.

The mean OTC binding to plasma proteins was 75.5 ± 4%. Following the drench route of administration the maximum plasma OTC concentration was achieved between 1 and 5 h post application and ranged between 1.18 and 1.41 μg/ml. The mean maximum plasma OTC concentration during medicated feed administration was 0.20 ± 0.06 μg/ml, which was achieved approximately 30 hours after the onset of the administration. A steady state OTC plasma level (approximately 0.2 μg/ml) was maintained till the end of the trial. Within 48 hours after cessation of medicated feed administration the plasma OTC levels were beneath 0.06 μg/ml. The mean OTC bioavailabilities of the oral routes were low: after the drench route of administration 9.0 ± 0.67%, and after medicated pelleted feed administration 3.69 ± 0.8%.

The mean OTC renal clearances of each piglet ranged between 10.1 and 13.9 ml/min/kg (based on free OTC plasma fractions). The renal OTC clearance values were urine flow dependent in all piglets and significantly correlated with the renal creatinine clearance (P< 0.005), being 3–5 times higher than the latter. It is concluded that in piglets OTC is excreted mainly by glomerular filtration and partly by tubular secretion. The potential clinical efficacy of 400 ppm OTC as medicated feed with respect to treatment, e.g. atrophic rhinitis, is discussed.     

Fluid and electrolyte therapy in ruminants.

Five important questions always must be asked and answered regarding fluid and electrolyte therapy in ruminants: (1) Is therapy needed? (2) What type of therapy? (3) What route of administration? (4) How much should be administered? and (5) How fast should the solution be administered? Food animal veterinarians routinely should carry the following commercially available crystalloid solutions and have the knowledge of how to use the products appropriately: Ringer's solution, 1.3% NaHCO3, acetated Ringer's solution, HS (7.2% NaCl), 8% NaHCO3, 23% calcium gluconate, calcium-magnesium solutions, and 50% dextrose. Ruminants with a blood pH less than 7.20 should be treated intravenously with 1.3% or 8.0% NaHCO3, and those animals with a blood pH greater than 7.45 should be treated intravenously with Ringer's solution. Oral electrolyte solutions or intravenous acetated Ringer's solution should be administered to ruminants with a blood pH greater than 7.20 but less than 7.45, and acetated Ringer's solution is preferred to lactated Ringer's solution. HS solution should be administered whenever rapid resuscitation is required. Oral administration of electrolyte solutions is underused in neonatal and adult ruminants. The optimal solution for oral administration to neonatal ruminants has a sodium concentration between 90 and 130 mmol/L; a potassium concentration between 10 and 20 mmol/L; a chloride concentration between 40 and 80 mmol/L; 40 to 80 mmol/L of metabolizable (nonbicarbonate) base, such as acetate or propionate; and glucose as an energy source. The optimal formulation for adult ruminants is unknown, but such a solution should contain sodium, potassium, calcium, magnesium, phosphate, and propionate to facilitate sodium absorption and to provide an additional source of energy to the animal. Acidemia is treated best by intravenous or oral administration of NaHCO3. Alkalemia is treated best by intravenous administration of Ringer's solution and oral administration of chloride-rich electrolytes such as KCl; the latter provides a physiologically more appropriate treatment than oral administration of vinegar or acetic acid solutions. Hypocalcemia is treated best by administering intravenous calcium borogluconate solutions or oral CaCl2 gels. Hypomagnesemia is treated best by intravenous or subcutaneous administration of combined calcium and magnesium solutions. Hypophosphatemia is treated best by oral administration of feed-grade monosodium phosphate. Hypokalemia is treated best by oral administration of feed-grade KCl; hyperkalemia is treated best by intravenous administration of 8.0% NaHCO3 or HS. The major challenges in treating fluid and electrolyte disorders in ruminants are making treatment protocols more practical and less expensive and formulating an optimal electrolyte solution for oral administration to adult ruminants.     

Increased bioavailability of tylosin phosphate as in-feed medication formulated for long-action pellets in broiler chickens

Circadian variation of serum concentrations of tylosin in broiler chickens after in-feed medication prompted a comparison study of the serum profiles of this drug after in-feed medication with standard tylosin phosphate (Tprf reference formulation group), and after in-feed medication with a sustained-release pellet formulation (Tpsr group), based on Patent No.MX/a/2012/013222 and PCT/MX2013/000137, in broiler chickens. Six hundred 4-week-old Ross broiler chickens were in-feed medicated with tylosin phosphate at an approximate dose of 25.2 mg/kg/d, based on daily feed consumption values and a final concentration of tylosin in feed of 200 mg/kg of feed. Approximately 2 to 3 mL of blood were obtained per 5 chickens every 2 h, avoiding the sampling of a bird more than once and during 72 h after making medicated feed available for the first time. Serum concentrations of tylosin were determined by HPLC. Gaussian multi-peak regressions were then fitted to serum concentration vs. time profiles. Day by d areas under the serum concentration vs. time profiles (AUC_0–24), as well as overall AUC_0–72, were statistically higher for the Tpsr group (P < 0.001). Also, maximum serum concentrations obtained and relative bioavailability for the Tpsr formulation were statistically higher (382.8%) as compared to the Tprf group (P < 0.01). Considering the referred improved values of AUC observed in the Tpsr formulation, as well as the fact that tylosin is a time-dependent antibacterial drug, better clinical responses are postulated with this pharmaceutical preparation intended for chickens. Tissue deposition studies for this new formulation of tylosin are required.     

Dispositions and residue depletion of enrofloxacin and its metabolite ciprofloxacin in muscle tissue of giant freshwater prawns (Macrobrachium rosenbergii)

Fates and residue depletion of enrofloxacin (ER) and its metabolite ciprofloxacin (CP) were examined in giant freshwater prawns, Macrobrachium rosenbergii, following either single oral (p.o.) administration of ER at a dosage of 10 mg/kg body weight (b.w.) or medicated‐feed treatment at the feeding concentration of 5 g/kg of feed for five consecutive days. The concentrations of ER and CP in prawn muscle tissues were measured simultaneously using high‐performance liquid chromatography (HPLC) equipped with a fluorescence detector. Muscle tissue concentrations of ER and CP were below the detection limit (LOD, 0.015 μg/g for ER; 0.025 μg/g for CP) after 360 and 42 h, following single p.o. administration respectively. Peak muscle concentration (C_max) of ER was 1.98 ± 0.22 μg/g whereas CP was measurable at concentrations close to the detection limit of the analytical method after p.o. administration at a single dosage of 10 mg/kg b.w. The concentration of ER in prawn muscle tissue with respect to time was analyzed with a non‐compartmental pharmacokinetic model. The elimination half‐life and area under the curve of ER were 39.33 ± 7.27 h and 168.7 ± 28.7 μg·h/g after p.o. administration at a single dose of 10 mg/kg·b.w. respectively. In medicated‐feed treated group, ER was detectable in prawn muscle tissue 11 days postdosing at the dose of 5 g/kg of feed for five consecutive days, which is the value corresponding to the maximum residue limit (MRL) of ER in animal products. The maximum concentrations of ER and CP were 2.77 ± 0.91 and 0.06 ± 0.006 μg/g during medicated‐feed treatment and postdosing respectively. The values of elimination half‐life and absorption half‐life of ER after single p.o. administration at a dosage of 10 mg/kg b.w. corresponded well with the values determined from medicated‐feed treated group, showing 41.01 ± 6.62 and 11.36 ± 3.15 h respectively in M. rosenbergii. Based on data derived from this study, to avoid the ER residue in prawn muscle, it should take at least 11 days postcessation of medicated feed containing ER at the dose concentration of 5 g/kg of feed twice a day at a rate of 1% of total body weight for five consecutive days to wash out the drug from the muscle of M. rosenbergii.     

3-Acetyl-4'-isovaleryl tylosin for prevention of swine dysentery

The 21 field isolates of Treponema hyodysenteriae which were tested were sensitive to 3-acetyl-4'-isovaleryl tylosin (AIV); the minimal inhibitory concentration was 0.25 to 16 micrograms/ml. 3-Acetyl-4'-isovaleryl tylosin administered prophylactically to pigs at concentrations of 5 to 100 mg/kg of feed and tylosin at 110 mg/kg of feed for 28 or 31 days prevented swine dysentery induced by tylosin-sensitive T hyodysenteriae strain SQ2; 15 nonmedicated, inoculated control pigs had bloody diarrhea, and 9 pigs died. In 2 additional trials, AIV administered prophylactically for 28 days at 55 or 110 mg/kg of feed prevented swine dysentery induced by tylosin-insensitive T hyodysenteriae strain B204. All of the inoculated principal pigs medicated with AIV at 55 or 110 mg/kg of feed or carbadox at 55 mg/kg of feed and the noninoculated sentinel pigs for each group had solid feces throughout the 56-day trial. In the nonmedicated, inoculated control groups, bloody diarrhea began at 4 to 5 days after inoculation was done, and 9 of 10 principal pigs and 6 of 9 sentinel pigs had dysentery; 2 pigs died. In the groups medicated with AIV at 27.5 or 5.5 mg/kg of feed, all 5 principal pigs and 3 or 4 sentinel pigs in each group had dysentery; 3 or 4 pigs in each group died. In the group medicated with tylosin at 110 mg/kg of feed, 7 of 10 principal pigs and all 9 sentinel pigs had dysentery; 1 pig died.(ABSTRACT TRUNCATED AT 250 WORDS)     

Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability

This work characterized the egg residual concentrations of albendazole (ABZ ) and its sulphoxide (ABZSO ) and sulphone (ABZSO ₂) metabolites and evaluated their effect on egg fertility and hatchability after ABZ treatments to laying hens. Seventy hens were allocated in groups: Group‐1 was the control without treatment; Group‐2 received a single ABZ oral dose (10 mg/kg); Group‐3, ‐4 and ‐5 were treated with ABZ in medicated feed over 7 days at 10, 40, or 80 mg kg^?1 day^?1, respectively. Eggs were analyzed to determine the ABZ /metabolite level by HPLC or subjected to incubation to evaluate the fertility and hatchability. Only ABZSO and ABZSO ₂ metabolites were quantified in egg after ABZ single oral administration with maximum concentrations of 0.47 ± 0.08 and 0.30 ± 0.07 μg/ml, respectively. ABZ and its metabolites were found in eggs after 7‐day ABZ treatments. The egg residue exposure estimated as AUC s (areas under the concentration vs . time curve) were 100.5 (ABZ ), 56.3 (ABZSO ) and 141.3 μg hr g^?1 (ABZSO ₂). ABZ administration did not affect the egg fertility at any dosages. Egg hatchability was not affected by ABZ treatment at 10 mg/kg in medicated feed, but it decreased when the dose was 4–8 times higher. These results should be considered when ABZ is used for deworming laying hens.     

Determination of florfenicol dose rate in feed for control of mortality in Nile tilapia infected with Streptococcus iniae

A dose titration study was conducted to determine the dosage of florfenicol (FFC) in feed to control Streptococcus iniae-associated mortality in Nile tilapia Oreochromis niloticus. Six tanks were assigned to each of five treatments: (1) not challenged with S. iniae and fed unmedicated feed; (2) challenged with S. iniae by injection and fed unmedicated feed; (3) challenged with S. iniae and given FFC at 5 mg/kg of body weight (bw) in medicated feed; (4) challenged with S. iniae and given 10 mg FFC/kg bw; and (5) challenged with S. iniae and given 15 mg FFC/kg bw. Treatment was initiated the day after inoculation, and feed was administered for 10 d. Cumulative mortality was 0% in the unchallenged, untreated group; 35.8 +/- 4.4% (mean +/- SE) in the challenged, unmedicated group; 19.2 +/- 2.7% in the 5-mg/kg treated group, 12.5 +/- 3.8% in the 10-mg/kg group, and 2.5 +/- 1.1% in the 15-mg/kg group. The cumulative mortality was significantly less in each challenged, FFC-treated group than in the challenged, unmedicated controls (5 mg/ kg: P = 0.0156; 10 mg/kg: P = 0.0007; 15 mg/kg: P < 0.0001). The efficacy of the 10- and 15-mg/kg FFC dosages was studied in a separate dose confirmation study. Fish in all tanks were injected with S. iniae. At 4 h postinoculation, 10 tanks were assigned to each of three feed treatments: (1) unmedicated feed; (2) 10 mg FFC/kg bw; and (3) 15 mg FFC/kg bw. Cumulative mortality was 20.5 +/- 2.0% in the challenged, unmedicated group; 11.0 +/- 2.1% in the 10-mg/kg group; and 5.5 +/- 2.4% in the 15-mg/kg group. Mortality was significantly less in the medicated groups than in the challenged, unmedicated control group (10 mg/kg: P = 0.0270; 15 mg/kg: P = 0.0007). Fish in both studies were necropsied, cultured for bacteria, and examined for gross lesions. The minimum inhibitory concentration of FFC against S. iniae in both studies ranged from 0.5 to 1.0 microg/mL. Florfenicol was palatable, safe, and efficacious for control of Nile tilapia mortality due to S. iniae infection.     

Control of bovine coccidiosis with monensin: in nonresistant newborn calves

Newborn Holstein male calves were purchased within 3 days after birth and were removed from the local farms to the Dixon Springs Agricultural Research Center. They were hand-fed for 7 weeks and then weaned to a prepared feed. Eight groups, each of 4 calves, were housed in separate pens. In each of 4 pens (pens 2 to 5), 1 calf was inoculated with sporulated oocysts of Eimeria bovis (and was not medicated); 1 calf was inoculated and given feed with added monensin at the dosage level of 10 g/906 kg of feed; and 2 calves were inoculated and given medicated feed with added monensin at the dosage level of 20 g/906 kg or 30 g/906 kg. In the 4 other pens (6 to 9), the calves were inoculated with E zuernii and otherwise were given feed without or with added monensin as in pens 2 through 5. Another group of 5 calves (all kept in 1 pen), served as noninoculated, nonmedicated controls. At 14 days after inoculations with E bovis, the single calves in each of the 4 pens that were given the nonmedicated feed began to show clinical signs of coccidiosis and discharged increasing numbers of oocysts. The other inoculated calves (given monensin) had fewer clinical signs and discharged fewer oocysts in the feces as the level of medication in the feed increased. The calves inoculated with E zuernii developed only moderately severe infections when compared with those inoculated with E bovis. Inoculated (with E bovis) nonmedicated calves had severe reductions in feed consumption and weight, and 3 of 4 died.(ABSTRACT TRUNCATED AT 250 WORDS)     

Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine

A 2 X 2 crossover design trial was conducted in gilts to determine the bioavailability and pharmacokinetics of tetracycline hydrochloride. The bioavailability of tetracycline hydrochloride administered orally to fasted gilts was approximately 23%. After intravascular administration, the disposition kinetics of tetracycline in plasma were best described by a triexponential equation. The drug had a rapid distribution phase followed by a relatively slow elimination phase, with half-life of 16 hours. Its large volume of distribution (4.5 +/- 1.06 L/kg) suggested that tetracycline is distributed widely in swine tissues. Total body clearance was 0.185 +/- 0.24 L/kg/h. Other pharmacokinetic variables were estimated. In a second trial, 3 gilts were fed a ration containing 0.55 g of tetracycline hydrochloride/kg of feed. Resulting plasma concentration of tetracycline was determined at selected times during 96 hours after exposure to the medicated feed. Plasma drug concentration peaked (0.6 micrograms/ml) at 72 hours after access to the medicated feed.     

欧盟禁用饲料药物添加剂的历史和法规

欧盟考虑到抗生素耐药性的发展和抗生素耐药基因可能从动物到人微生物的转移,决定从2006年1月1日起禁止抗生素作为生长促进剂,甚至还建议禁止在动物饲料中全面使用所有的抗菌剂。收集和整理欧盟饲料药物添加剂的禁用清单和法规,介绍欧盟禁用饲料药物添加剂的历史及其对动物健康的影响,以期为中国饲料药物添加剂的使用和管理提供借鉴和参考。     

Coccidiostatic action of monensin fed to lambs: body weight gains and feed conversion efficacy.

Thirty crossbred ewe lambs weighing an average of 37.3 kg were allotted to 6 groups of 5 lambs each so that group weights were nearly equal. Lambs were fed dehydrated alfalfa pellets, initially at 1.14 kg/day and subsequently increased after experimental day 15 and 42. Each lamb was artificially infected with 18,000 sporulated oocysts of Eimeria ninakohlyakimovae. Groups 1, 2, 3, and 4 were given monensin in the form of medicated alfalfa pellets at dose levels of 5, 10, 20, and 30 g/metric ton, respectively. Groups 5 and 6 were infected controls (infected, nonmedicated). Lambs in groups 5 and 6 developed severe clinical coccidiosis, having diarrhea and losing weight rapidly. Group 1 lambs did not have diarrhea, but the lambs did not gain well. All other medicated lambs gained weight during the experimental period of 84 days. Feed conversion was good in medicated groups 2, 3, and 4 and was poor in control groups 5 and 6. Statistically significant differences in feed conversion and body weight gains (5 and 1% level of confidence) were observed between control and medicated groups.     

Circadian serum concentrations of tylosin in broilers after feed or water medication

1. Because tylosin is a time-dependent antibacterial agent, and because feeding and drinking of broilers decreases in late afternoon and ceases in the dark, it was hypothesised that serum concentrations of this drug are greatly reduced during the dark period. 2. The trial was carried out in a commercial poultry house, under standard broiler husbandry conditions, with food and water withdrawn from 22:00 until 07:00 h next morning and exposed to a natural light cycle of 13L:11D. 3. Broilers were given tylosin tartrate, in either feed or water, for 5 d as follows: 100, 200 and 300 ppm in feed, equivalent to 12.6, 25.2 and 37.8 mg/kg/d, respectively; and 200 and 400 mg/l in drinking water, equivalent to 51 to 102 mg/kg/d, respectively. 4. At 07:00 h on d 4, and for the next 40 h, hourly serum samples were obtained and analysed for tylosin by means of a microbiological assay. 5. Day vs night concentrations of tylosin expressed as area under the curve (AUC) in all groups revealed greater values during the day. The highest AUC and AUC(24)/minimal inhibitory concentration (MIC) ratio were obtained in the group medicated with 400 mg/l and the corresponding lowest values were found in the group medicated with 100 ppm in feed. 6. In conclusion, tylosin did not reach therapeutic serum concentrations during the dark period, at all dose rates tested when administered in feed or water. A sustained release form of this drug is needed to solve this inadequacy of tylosin medication in broilers.     

畜禽饲粮配合新思路:多配方平行设计

多配方平行设计是另一类畜禽饲粮配合方法,本研究旨在将这种方法应用于动物饲料配方。采用不同组合的多配方平行设计同时配合了生长猪7个不同阶段猪群的饲粮,比较与分析饲粮单位价格、原料用量和养分含量。通过这种设计方法产生的49个生长猪饲粮配方的能量、钙、磷、粗蛋白质、氨基酸、总氮和矿物质的养分含量,都达到或超过美国国家研究委员会(2012)提出的猪营养需要的推荐量,也满足最低成本的要求。实例表明,多配方平行设计能同时配合多个畜禽饲粮,并能在一个大的范围内选到更好的配方,应用于动物饲料配方设计具有实际可行性。     

Evaluation of lasalocid as a coccidiostat in calves: titration, efficacy, and comparison with monensin and decoquinate

Two experiments were conducted to evaluate lasalocid as a coccidiostat in Holstein calves and to compare lasalocid with monensin and decoquinate. In experiment 1, calves in 3 groups (6 calves/group) were each inoculated with 500,000 sporulated oocysts, 88% of which were Eimeria bovis and 12% were E zuernii. Calves in each group were given lasalocid-medicated feed at 0.50 (group 3), 0.75 (group 4), or 1 mg/kg (group 5) of body weight/day for 45 days. Two control groups (6 calves/group) were also evaluated; calves in control group 2 were inoculated and nontreated, and calves in control group 1 were noninoculated and nontreated. At 0.50, 0.75, or 1 mg/kg/day, lasalocid was equally effective in preventing induced coccidiosis (E bovis and E zuernii) in calves. Compared with inoculated nontreated controls, treated calves had significantly (P less than 0.05) fewer oocysts in feces and had fewer clinical signs of coccidiosis from days 16 to 30 after inoculation. Experiment 2 was conducted to compare the effectiveness of monensin, lasalocid, and decoquinate for the prevention of experimentally induced coccidiosis. Calves (n = 48) were allotted into 4 groups (12 calves/group); each was inoculated orally with 275,000 sporulated oocysts, predominantly E bovis and E zuernii, and each was given nonmedicated feed (group 6) or feed medicated with 33 mg of lasalocid (group 7), decoquinate (group 8), or monensin (group 9)/kg of feed for 46 days. Calves given medicated rations had significantly (P less than 0.05) fewer oocysts in their feces and fewer clinical signs of coccidiosis than did calves given nonmedicated rations.(ABSTRACT TRUNCATED AT 250 WORDS)     

Branching patterns of the adrenal arteries in the degu (Octodon degus)

The degu has drawn increasing attention for use as an experimental animal in stress response studies due to its physiological features, such as diurnality and seasonal breeding, which differ from conventional laboratory rodents. Stress response is elicited by steroid hormones secreted by the adrenal gland, whose functions are controlled by pituitary hormones reaching through the adrenal arteries. However, knowledge of the arterial anatomy of the degu adrenal gland remains insufficient. To address this issue, we observed adrenal arteries in 20 male degus injected with red-colored latex. Adrenal arterial branching patterns were classified into Types 1–4, which respectively have 1 to 4 parent arteries that give rise to the adrenal arteries. Based on the combination of the parent arteries, Types 2 and 3 were categorized into subtypes a to c, while Type 4 was categorized into subtypes a and b. On the left side, Type 2 (45%) and Type 3 (45%) were predominant, whereas Type 1 (5%) and Type 4 (5%) were infrequent. On the right side, Type 2 (50%) and Type 3 (45%) were predominant, whereas Type 4 (5%) was infrequent. Type 1 was not present. There were 0 to 4 cranial, 1 to 4 middle and 1 to 4 caudal adrenal arteries, with the total number varying from 2 to 9. The present observation provides knowledge of comparative anatomical features of the degu adrenal arteries, which can serve as an anatomical basis for comparative endocrinological studies.     

Effect of efrotomycin in feed on the quantity, duration, and prevalence of shedding and antibacterial susceptibility of Salmonella typhimurium in experimentally infected swine

The influence of efrotomycin administered at the rate of 16 mg/kg of feed in 10 Salmonella typhimurium-inoculated pigs was determined by comparing this group with a group of 10 pigs inoculated with S typhimurium that were given nonmedicated feed. Two control groups of 4 noninoculated pigs each, 1 group medicated with efrotomycin at 16 mg/kg of feed, the other nonmedicated, also were evaluated. An inoculum of 1.7 x 10(10) colony-forming-units/pig induced colonization of S typhimurium in all 20 pigs. Evaluation of the quantity of shedding did not reveal a clear or consistent treatment-related increase in S typhimurium counts; mean differences between the nonmedicated and medicated groups never exceeded 1 log unit. On the last day of the study (day 56 of the medication), 8 nonmedicated and 9 medicated pigs were determined to be infected with S typhimurium via enrichment procedures, so there was no difference in duration of shedding, and there were no significant differences in prevalence of shedding between the nonmedicated and medicated groups at any of the sampling times. Of 1,340 S typhimurium colonies isolated from the nonmedicated and medicated groups, 1,330 were susceptible to all 12 antibacterials tested, indicating no treatment-related effect on susceptibility. At necropsy, S typhimurium was not isolated from any liver or spleen specimens, and was isolated from only 2 of 20 lymph nodes. However, S typhimurium was isolated via enrichment from the cecal contents from all 20 pigs. There were no treatment-related differences in feed consumption, weight gain, or feed efficiency. Appreciable differences in the measurements were not found between the efrotomycin-medicated and nonmedicated pigs.     

Serum and tissue concentrations of doxycycline in broilers after the sub-cutaneous injection of a long-acting formulation

1. The antibacterial agent doxycycline hyclate (Dox) is usually administered to broilers in drinking water or as a feed supplement. Parenteral injection is not the usual route for administration, so a long-acting formulation (Dox-LA) was tested to evaluate if serum concentrations can achieve the pharmacokinetic/pharmacodynamic (PK/PD) ratios regarded as adequate for the drug.

2. A poloxamer-based matrix was used to provide Dox-LA. Serum and tissue concentrations of Dox vs time were determined in two day-old broilers after subcutaneous (SC) injection of Dox-LA or oral administration of a single bolus of aqueous Dox (Dox-PO), at a dose of 20?mg/kg. Weight gain, feed conversion rate, haematological variables, aspartate aminotransferase and alanine aminotransferase activities, blood urea and creatinine were determined and compared for Dox-LA with Dox-PO and non-medicated controls.

3. Dox-LA had a high relative bioavailability (1200%). Maximum serum concentrations were not statistically different (5·1?±?1·1?µg/ml for Dox-LA and 6·1?±?1.4?µg/ml for Dox-PO), but half-life of Dox-LA was much greater than the value obtained for Dox-PO (73·0?±?0·9?h and 2·0?±?0·02?h, respectively). Tissue concentrations were higher, and stayed higher for longer periods in the Dox-LA group.

4. In conclusion, considering the minimum effective serum concentration against Mycoplasma spp is 0·5?µg/ml, a dose-interval of 180?h can be achieved with Dox-LA, but only for 24?h after Dox-PO. Better PK/PD ratios for Dox-LA should result in improved clinical outcomes compared with Dox-PO.     

Response of growing goslings to dietary methionine from 28 to 70 days of age

1.?A dose–response experiment with 5 dietary methionine concentrations (2?3, 3?3, 4?3, 5?3 and 6?3 g/kg) was conducted with goslings to estimate the growth performance and carcase quality response of growing goslings to dietary methionine from 28 to 70 d of age.

2.?A total of 150, 28-d-old birds were randomly distributed to 15 pens with 10 birds per pen according to similar pen weight. There were 5 dietary treatments, each containing three replicate pens. Weight gain, feed intake and feed/gain of goslings from each pen were measured at 2-week intervals from 28 to 70 d of age. At 70 d of age, 4 goslings were selected randomly from each pen and slaughtered to evaluate carcase quality.

3.?Significant effects of dietary methionine on daily weight gain (28–56 d) and daily feed intake were determined. Daily weight gain from 28 to 42 d and 28 to 56 d, daily feed intake and gain/feed showed significant quadratic response to increasing dietary methionine, while abdominal fat proportion showed a significant linear response.

4.?When dietary CP concentration was 158?2 g/kg, the optimal methionine concentrations for growing goslings from 28 to 42 d and 28 to 56 d of age for maximum daily weight gain were 4?07 and 4.14 g/kg, respectively.     

Evaluation of conjugated linoleic acid and dietary antibiotics as growth promotants in weanling pigs.

An experiment was conducted to determine the efficacy of dietary conjugated linoleic acid (CLA) as a growth promotant in weanling swine. Weanling pigs (n = 192; 7.6 kg and 29 d of age) were randomly assigned to four treatments that were arranged as a 2 x 2 factorial. Concentrations of dietary CLA (0 or 0.6%) and antibiotics (+/-) constituted the main effect variables. Dietary CLA treatments consisted of a 1% addition of an oil containing 60% CLA isomers or 1% soybean oil, and dietary antibiotic treatments were antibiotics or no antibiotics. The experimental diets were fed for 9 wk in four phases (1, wk 1; 2, wk 2 and 3; 3, wk 4 through 6; and 4, wk 7 through 9), after which all pigs were fed identical medicated diets for the duration of the finishing phase. Live weights were recorded at wk 17 postweaning and at marketing to determine any residual effects of dietary treatments on finisher ADG and days to market. Medicated diets fed during phases 1 and 2 contained 55 mg carbadox/kg; during phase 3 contained 299 mg tilmicosin/kg; and during phase 4 contained 110 mg tylosin and 110 mg sulfamethazine/kg. Pigs fed medicated diets had higher overall ADG than pigs fed unmedicated diets for wk 0 through 9 (P < 0.03). Gain:feed (G:F) was greater for pigs fed medicated diets than for pigs fed unmedicated diets during phase 1 (P < 0.03) and for the duration of the nursery phase (P < 0.03). There were no effects of CLA on ADG, ADFI, or G:F. There were no residual effects of nursery CLA or antibiotics on finisher ADG and days to market. Blood samples collected from a subset of pigs (n = 72) at the completion of phases 2, 3, and 4 were assayed for serum IGF-I and antibody concentrations to porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae. There was a tendency for pigs fed medicated diets to have greater IGF-I concentrations than pigs fed unmedicated diets at the completion of phase 4 (P < 0.06). Pigs fed CLA had greater antibody titers (P < 0.02) to Mycoplasma hyopneumoniae at d 63 than pigs fed diets without CLA. These results indicate that feeding 0.6% dietary CLA did not enhance growth performance in weanling swine and that the use of dietary antibiotics can increase production efficiency in nursery pigs. Furthermore, there were no interactions between CLA and dietary antibiotics on the variables addressed in this study.